About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Efficacy of ART to Interrupt HIV Transmission Networks

NCT02528773·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of California, San Diego

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Age ≥18 years of age
2. Newly diagnosed HIV infection
3. ART naïve (≤7 days ART, previous use of PEP or PrEP are not exclusions)
4. Subject must be able to provide written consent
5. Subject must agree to study specific specimen collections and visit schedule.

You may not be if

1. Any factor or factors that in the opinion of the local investigator that could prevent compliance with study requirements.
2. Contraindication to phlebotomy or specimen collection.

The record

StatusCompleted

PhaseNo phase

Taking part256

StartedSep 2014

UpdatedNov 4, 2020

Conditions

Where1

UCSD AntiViral Research Center
San Diego, California, United States

Clareo Health | Efficacy of ART to Interrupt HIV Transmission Networks